Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension.
Dalia D HadiMohammed Dheyaa Marsool MarsoolAli Dheyaa Marsool MarsoolNeel VoraSajjad G Al-BadriNabeel H K Al-FatlawiAmeer F Abbas Al WssawiAbdullah M T Al-IbraheemKhadija A HamzaPriyadarshi PrajjwalMohammed A MateenOmniat Amir HussinPublished in: Immunity, inflammation and disease (2023)
The advancements discussed in this review hold the promise of improving the quality of life for IPF patients and enhancing our understanding of this condition. There remains a need for further research to confirm the efficacy and safety of new IPF treatments and to develop more effective strategies for managing exacerbations.
Keyphrases
- idiopathic pulmonary fibrosis
- pulmonary hypertension
- interstitial lung disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic obstructive pulmonary disease
- cystic fibrosis
- prognostic factors
- peritoneal dialysis
- pulmonary artery
- rheumatoid arthritis
- big data
- coronary artery
- deep learning
- systemic sclerosis